

TPCA-1

Catalog No: tcsc0045

Available Sizes

Size: 5mg

Size: 10mg

Size: 100mg

Specifications

CAS No:

507475-17-4

Formula:

 $\mathsf{C}_{12}\mathsf{H}_{10}\mathsf{FN}_3\mathsf{O}_2\mathsf{S}$

Pathway:

NF-ĸB

Target:

IKK

Purity / Grade:

Solubility: 10 mM in DMSO

Observed Molecular Weight:

279.29

Product Description

TPCA-1 is a potent and selective inhibitor of **IKK-2** with IC_{50} of 17.9 nM.

IC50 & Target: IC50: 17.9 nM (IKK)


In Vitro:

Copyright 2021 Taiclone Biotech Corp.



TPCA-1 significantly represses pro-inflammatory cytokines IL-8 and GRO- α in NPECs^[1]. TPCA-1 inhibit NF κ B activity as well as glioma cell proliferation and IL8 expression, and at concentrations of 2.5 and 5 μ M, it blocks the TNF-induced p65 translocation into the nucleus of U87 cells^[2]. TPCA-1 inhibits lipopolysaccharide-induced human monocyte production of TNF- α , IL-6, and IL-8 with an IC₅₀ =170 to 320 nM^[3].

In Vivo: TPCA-1 (3, 10, or 20 mg/kg, i.p.) results in a dose-dependent reduction in the severity of murine collagen-induced arthritis (CIA). TPCA-1 (10 mg/kg, i.p., b.i.d.) in vivo results in significantly decreased collagen-induced T cell proliferation ex vivo^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.